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Abstract  
Objective: Clozapine is the only evidence-based antipsychotic for treatment-resistant 
schizophrenia. However, it has considerable side-effects, limiting its usability and reducing 
patients’ adherence. One of the most common and distressing side-effects is 
hypersalivation, which can be debilitating, stigmatizing and potentially dangerous through 
its association with aspiration pneumonia.  There is a paucity of evidence guiding possible 
treatment strategies for hypersalivation. The current study aims to examine the efficacy of 
hyoscine (scopolamine) for clozapine-induced hypersalivation.  
Methods: Fourteen inpatients diagnosed with treatment-resistant schizophrenia, treated 
with clozapine and suffering from hypersalivation were randomised to receive hyoscine 
0.3mg and placebo daily for 4 weeks each in a randomised, double-blind, placebo-
controlled crossover trial. The primary outcome was improvement in the Toronto 
Nocturnal Hypersalivation Scale. Secondary outcomes were change in mass of the 
pillowcase, anxiety, depression and quality of life. 
Results: hypersalivation significantly improved with hyoscine over placebo when 
measured by the Toronto Nocturnal Hypersalivation Scale (odds ratio 0.21, 95% CI 0.16– 
0.28, p<0.001). No significant difference was observed in any of the secondary outcomes.  
Conclusion: This study demonstrated a beneficial effect of hyoscine over placebo for 
clozapine-induced hypersalivation. 
Keywords: Schizophrenia, Clozapine, Treatment Resistant, Hyoscine, Scopolamine, 
Sialorrhea.  
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Introduction  
Clozapine is uniquely effective in treatment resistant schizophrenia, (McEvoy et al., 2006; 
Siskind et al., 2016) and is the only antipsychotic licensed in the UK for this indication 
(Mortimer, 2003). However, it is associated with multiple and severe adverse effects 
which seriously limit its tolerability and disrupt adherence (Yusufi et al., 2007; Taylor et al., 
2009; Pai and Vella, 2012). Strategies to manage these adverse effects are in great need, 
in order to improve quality-of-life. 
One of the most common and disabling adverse effects associated with clozapine is 
hypersalivation, which is more prominent during night-time (Ben-Aryeh et al., 1996; 
Waserman and Criollo, 2000). The pathophysiology whereby clozapine induces 
hypersalivation is not clear and several possible mechanisms have been suggested, such as 
muscarinic M4 receptor antagonism, alpha-2 adrenergic antagonism and oesophageal  
dysfunction (Zorn et al., 1994; Ben-Aryeh et al., 1996; Praharaj, Arora and Gandotra, 
2006). 
Several studies have indicated that hypersalivation is one of the most common side-
effects of clozapine (>80%) (Hodge and Jespersen, 2008; Maher et al., 2016), could have a 
substantial effect on the patient’s quality-of-life (Maher et al., 2016), and is an important 
reason for non-adherence with the treatment (Praharaj, Arora and Gandotra, 2006). 
Hypersalivation may lead to social embarrassment (Praharaj, Arora and Gandotra, 2006) 
and speech disturbances and may increase the risk of aspiration pneumonia (Hinkes et al., 
1996). However, there is a paucity of clinical trials examining possible treatment strategies 
to alleviate hypersalivation (Praharaj, Arora and Gandotra, 2006). A Cochrane review of 
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the existing studies concluded that the evidence was poor, with lack of clinical data, poor 
reporting on allocation concealment and randomization, unconfirmed diagnoses, short-
term follow-up and inconsistent  outcome measures (Syed et al., 2008). Recently, few 
papers attempting to overcome the evidence gap has been published, examining common 
yet not-evidence-based treatments, such as Hyoscine [Ref] and Glycopyrrolate [ref].  
Hyoscine hydrobromide, known as scopolamine in the United States, is a competitive 
muscarinic antagonist, and is one of the most commonly prescribed treatments for 
clozapine-induced hypersalivation in the UK (Kasmi, 2014; Taylor, Paton and Kapur, 2015).  
It is listed as an unlicensed medication indicated for Clozapine-Induced hypersalivation 
(CIH) in the British National Formulary (Joint Formulary Committe, 2015). However, there 
is only one publication of  a randomized control trial, which examined the effects of a 
short-period Hyoscine ointment treatment and yielded negative results, and the evidence 
supporting its use is based only on published case reports. Therefore, there is an urgent 
need to address this gap in the evidence base (Chu et al., 2015). 
In the current study we have conducted a randomized, double-blind, placebo controlled, 
crossover trial aimed to assess the efficacy and safety of hyoscine hydrobromide in the 
treatment of CIH.    
 
Methods 
Trial design    
6 
 
The study was a double-blind, placebo-controlled crossover design. Randomization was 
equal (1:1). 
Participants 
Participants were recruited from inpatient psychiatric units at the Bethlem Royal Hospital, 
a part of the South London and Maudsley NHS Foundation Trust. Patients were eligible to 
participate in the study if they met the following inclusion criteria: 
A. Diagnosis of Schizophrenia or Schizoaffective disorder as per DSM IV-TR criteria.   
B. Receiving clozapine for at least two weeks.   
C. Clozapine dose in the range 200 – 900 mg per day.   
D. A minimum score of 2 on the Toronto Nocturnal Hypersalivation Scale, defined as 
moderate or worse, on at least 4 occasions within 28 days prior to randomisation.  
E. Aged between 18 and 65 years of age.   
F. Capable of understanding the information given and giving fully informed consent 
prior to any study specific procedures.  
Patients were excluded if they met any of the following exclusion criteria: 
A. Medical conditions that could influence hypersalivation (e.g. idiopathic Parkinson’s 
Disease).   
B. History of an allergic reaction to hyoscine hydrobromide.   
C. Any of the following contra-indications to hyoscine as stated in the British National 
Formulary and electronic Medicines Compendium: Prostatic enlargement, 
myasthenia gravis, pyloric stenosis, paralytic ileus, glaucoma and pregnancy (see 
appendix C).   
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D. A woman of childbearing potential, who has tested negative for pregnancy, or is 
unable or unwilling to use appropriate contraception during the study.    
E. Participation in another therapeutic study within the preceding 12 weeks or use of 
other investigational drugs or agents.   
F. Lack of capacity to provide informed consent to the proposed intervention.  
The study was approved by the South-East Research Committee (REC) and was registered 
at the clinical trials database EudraCT, registration number 2009-016300-23. 
Intervention 
The study began with a 7-day washout period in which no treatment for hypersalivation 
was given to the participants. This length of the washout was determined according to the 
half-life of common medications being used to treat hypersalivation. The patients were 
then randomly assigned to receive either oral hyoscine hydrobromide 0.3mg or placebo.  
Both the hyoscine tablets and the placebo, comprised of lactose granules, were over-
encapsulated, and were identical in mass, taste and appearance. Treatment was 
administered at 10pm for 28 days. This first period was followed by another 7-days 
washout, following the patients cross-over to the other arm (e.g. receiving placebo if 
being administered hyoscine at the first period, and vice versa), for an additional 28 days. 
Assessments of primary and secondary out comes were performed in the same manner in 
both periods. The trial lasted 70 days, from the beginning of the first washout period to 
the end of the second arm. The study procedure is illustrated in figure 1. 
Primary outcome 
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The primary outcome measure was the Toronto Nocturnal Hypersalivation Scale (TNHS), 
which was developed by combining the Drooling Severity and Frequency Scale (Rashnoo 
and Daniel, 2015), which rates daytime drooling, with the Nocturnal Hypersalivation 
Rating Scale (Spivak et al., 1997), which focuses on nocturnal hypersalivation. The TNHS is 
a 5-point self-rated scale ranging from 0 (no hypersalivation) to 4 (very severe 
hypersalivation, awakening due to hypersalivation), and has  been used in prior studies to 
measure hypersalivation (Sockalingam, Shammi and Remington, 2009). TNHS scores were 
recorded daily throughout the study. 
Secondary outcomes 
To obtain an objective measure of the amount of saliva coating the pillow and given 
criticism that was presented in the literature regarding previous measures (such as 
diameter of drooling on the pillow), we measured the change in mass of the pillowcase. 
The patients were given pillows with a waterproof plastic coating, so that any saliva would 
be absorbed by the pillowcase, and not into the pillow itself.  Disposable paper 
pillowcases were used. Every evening before the patient retired to bed, a new, dry 
pillowcase was weighed and put on the pillow.  The following morning, the pillowcase was 
removed and weighed between 8-9am. The difference in weight was the outcome 
measure.  
Anxiety and depression were measured using the Hospital Anxiety and Depression score 
(HADs), which is a 14-item self-rated questionnaire, each item on a scale of 0 to 3 
(Zigmond and Snaith, 1983). Quality of life was measured by EuroQol 5-Dimensions 
questionnaire (EQ-5D), a self-rated questionnaire containing 5 domains (mobility, self-
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care, usual activities, pain/discomfort and anxiety/depression), scored on a scale ranging 
from “I have no problems in [specific domain]” to “I’m unable to [function in that 
domain]” (Brooks, Rabin and De Charro, 2013). The HADS was recorded once-a-week 
throughout the study, while the EQ-5D was recorded at the beginning and the end of each 
period (active/placebo). Adverse Events were logged through all the study phases by the 
ward clinical team administering the treatment. 
Sample Size 
A power calculation was performed using G*Power 3.0 for Mac OS X.  Using repeated 
measures ANOVA, a sample of 12 participants, each giving 24 measures in each arm would 
have 80% power to detect an effect size of ≥0.34 (small to moderate) in the primary 
outcome measure, the TNHS, at the p≤0.05 level, assuming a correlation among repeated 
measures of 0.3.  
Randomization 
Patients were allocated with serial numbers and equally block-randomized (1:1, blocks of 
two) by an online randomisation service provided by the Mental Health and Neuroscience 
Clinical Trials Unit (MH&N CTU) of the Institute of Psychiatry Psychology and Neuroscience 
at King’s College London. Participants were randomised to receive either hyoscine 
hydrobromide 0.3mg or placebo, once daily. The randomization service generated emails 
for the pharmacist, indicating kit number that was then returned to the ward.  
Blinding 
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Assignment to either hyoscine or placebo was blinded to the participants, investigators 
and pharmacy (double-blind). Blinding of the patients and treating physicians and nurses 
to the allocation status was assured by identical capsules appearance (over-encapsulation) 
and by identical labelling. Over-encapsulation, packaging and labelling took place at Guy’s 
and St. Thomas’ Foundation Trust Manufacturing Unit. Blinded packs of study medication 
were sent to the site pharmacy. Once an eligible in-patient completed the baseline 
assessment and provided written and informed consent, online randomisation was 
requested. Emails containing the treatment kit allocation were automatically generated to 
the requestor, the Chief Investigator, the site pharmacist and the trial manager. A study 
specific prescription was completed and sent to the site pharmacy for dispensing. The 
confirmation email was attached to the study prescription, and cross-checked against it, at 
the point of dispensing.  
Statistical Analysis   
The analyses were pragmatic, based on Intention-To-Treat and utilised all available follow-
up data with the trial statistician blind to treatment sequence. The primary outcome 
variable, TNHS, is ordinal and was analysed using proportional-odds regression. A random 
intercept for each subject with mean zero and unknown variance to be estimated by the 
model allowed for within-subject clustering of the repeated measurements. As change 
over time may be different for different patients, day was also included as a random 
covariate. The correlation structure of the random effects was assessed using likelihood 
ratio tests.  
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As defined, the primary analysis model estimated the mean odds ratio for being in a 
different TNHS category in the active arm relative to placebo arm.  The treatment 
estimate was adjusted for baseline TNHS score, trial period (first or second arm) and day 
(within period).  Baseline TNHS score adjusts for differences according to baseline 
hypersalivation level; the inclusion of period adjusts for potential order effects for 
treatment versus control phases and day adjusts for (linear) change in condition within 
each treatment period.  
Analysis of morning pillow weight used a linear mixed model with the same fixed and 
random effect structure but with identity link and normal errors. The HADs analysis used 
linear mixed models excluding day as measures were taken once at the end of each 
treatment period. Change of EQ-5D scores were assessed using the Wilcoxon matched 
pairs-signed rank test.  Data management was done in R 2.15 and proportional odds and 
regression models were fitted in STATA 14.1 and GLLAMM package (Rabe-hesketh, 
Skrondal and Pickles, 2004).  
 
Results   
Fifteen patients were screened for eligibility, one of them did not wish to enter the study. 
Due to an error, he was randomized, though did not participate in any part of the study. 
Thus, the division between the two arms (first-placebo vs. first-treatment) was 8:6, rather 
than 7:7. Out of the 14 participants entering the trial, one withdrew during the first arm, 
one during the second arm, and one during the second washout period, thus 11 
participants completed the trial. The CONSORT diagram is presented in Figure 2. The mean 
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age of participants was 38.7 [SD 12.0] years, 29% were female and 43% non-white. The 
baseline characteristics of the participants are presented in Table 1. 
Outcomes 
All outcome measures are presented in table 2. Hypersalivation as measured by TNHS 
ratings (defined as the primary outcome measure) improved significantly: the odds of 
higher ratings (reflecting greater severity of salivation) were much lower in the period of 
hyoscine treatment compared to placebo (OR 0.21, 95% CI: 0.16 – 0.28, p < 0.001). The 
data is illustrated in figure 3.  For the secondary outcome measures, there was no 
difference in the daily pillow-weight measure between the treatment and placebo periods 
(x2(1)=0.00, p>0.1). However, it is important to mention that 50% of the pillow-weight 
sampling data was missing, mainly due to displacement of the pillowcases and untimely 
collection of the sample. HADs scores, for both anxiety and depression, did not yield a 
significant change (X2(1)=0.26, p>0.1 and X2(1)=0.1,p>0.1, respectively). Finally, EQ-5D 
showed no difference in quality of life between treatment periods for all the domains and 
the visual analogue scales (all p>0.1). 
Adverse events 
There were no serious adverse events recorded during the study. Overall there were 
fewer adverse events recorded in the administration periods relative to the washout, and 
even fewer differences between the active and the placebo administration Adverse events 
per organ systems and intervention arm are presented in table 4. 
Discussion 
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This is the first study to examine the common clinical practice of prescribing hyoscine in 
cases of CIH by a randomized controlled trial. The results show that hyoscine 0.3mg once 
daily was able to reduce severity of hypersalivation, as reported by the TNHS. None of the 
secondary outcome measures – mass change of pillowcase, anxiety, depression and 
quality of life were significantly different between the active and placebo arms. Hyoscine 
was well tolerated, with rates of adverse events in active treatment similar to rates in the 
placebo and washout periods. The current study shows that the use of hyoscine 0.3mg 
once daily is an effective and safe treatment for reduction of clozapine-induced 
hypersalivation. Hyoscine treatment was not associated with changes in any of the 
secondary outcomes. The change in weight of the pillowcase did not prove useful and 
contained high degree of missing data.  
Limitation 
The relatively short follow-up period does not allow us to assess the efficacy and safety of 
a long-term hyoscine treatment. Though rates and type of adverse events did not differ 
during the intervention, it should be noted that the small sample size might not have been 
powered to detect subtler changes. Furthermore, adverse reactions might be more 
pronounced in a longer-term treatment period, especially due to the anti-cholinergic 
effect of hyoscine that might aggravate the constipation often reported with clozapine.   
The sample size was lower than planned, due to 4 patients revoking their participation or 
discontinuing the trial. Despite the modest sample size, a significant difference was 
measured in the main outcome measure, pointing to a substantial effect-size of hyoscine. 
However, it is possible that this study was under-powered to detect changes in the 
14 
 
secondary outcomes, even more so due to the four patients discontinuing the trial, that 
led to a smaller sample size than originally planned. It should be noted that while the 
number of patients was modest, the study used repeated measures analysis, thus 
including 77 measurement points, which increased the statistical power of this study. 
Moreover, the cross-over approach allowed us to measure within subject differences 
between treatment and placebo conditions. Furthermore, the major limitations of cross-
over design were addressed by a wash-out period (minimizing the “cross-over” effect) and 
adjusting for order-effect.  
 
Generalisability 
Although the sample size was small, patients were from both genders and ethnically 
diverse. While the study was performed in an inpatient-setting due to the close follow-up 
needed, it seems that the lack of serious adverse-effect and even lack of increase in side-
effects ratio indicates that hyoscine can be administered safely at outpatient clinics as 
well. It should be noted that the current results contradict those of a previous RCT done 
with Hyoscine ointment [REF]. It is possible that Hyoscine tablets are more effective than 
ointment. Additional explaining might stem from the ethnically and genetically different 
sample as the mentioned study was conducted in Japan. More importantly, the said study 
did not reveal increased salivation in the Clozapine treated patients, possibly due to 
relatively low doses of clozapine (mean dose of 136.1), thus the possible effect of hyoscine 
might not have been evident. 
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A Cochrane review covering randomized control trials of possible treatment strategies of 
CIH recommended future studies with clear reporting of randomization and blinding 
processes, diagnosis, clozapine dosage and treatment duration, with longer follow-up, and 
a valid and reliable scoring system (Syed et al., 2008). The current study answers most of 
the scientific gaps noted.  All the patients met DSM-IV criteria for schizophrenia or 
schizoaffective disorder. We used the TNHS, a measure that is equivalent and designed to 
be more comprehensive than the Nocturnal Hyper-Salivation Rating that had been 
suggested in prior literature. Furthermore, we attempted to devise an alternative 
objective measure to nocturnal hypersalivation. The common method in studies published 
(Syed et al., 2008) was the diameter of the saliva stain in the morning suffers from several 
drawbacks, such as difficulties to measure asymmetry, type of fabric, mobility of the saliva 
due to participants’ movements at night. Therefore, we attempted to devise an improved 
measure using change in weight of the pillowcase overnight. This method was found to 
have several drawbacks, which might impact its reliability: the effect of room temperature 
on evaporation; the patients’ sleep duration; the lag between the patients waking up and 
the ward nurses collection of the pillowcase and the possibility some fraction of the saliva 
was not soaked in the pillowcase, but rather on the bedsheets, as a result of the patients’ 
movements at night. Moreover, in our study, a high percentage of the pillowcase-mass 
data was missing due to technical problems, jeopardizing the validity of any conclusion.  
While several studies have noted the importance of hypersalivation as a side-effect and its 
possible effect on quality-of-life (Waserman and Criollo, 2000), our study did not detect 
the expected improvement in quality-of-life following the reduction of hypersalivation. It 
is possible that, while disturbed by hypersalivation, the patients’ quality of life in 
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inpatients with treatment refractory schizophrenia is dominated by many other prominent 
factors, such that a change in single side-effect would not be translated into an overall 
improvement of quality of life.  
 
Conclusions 
Hyoscine seems to be an effective and safe method of treatment to CIH, and this study 
provides evidence to support the common clinical practice of prescribing hyoscine in such 
an indication. However, the results emphasize the need for additional, longer and larger 
trials, examining hyoscine and other treatment strategies for CIH – and comparing them to 
one another in randomized blinded studies. Furthermore, the study suggests the 
importance of devising better objective methods to quantify hypersalivation. 
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Figure 1. Study procedures outline. 
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Figure 2. CONSORT diagram showing the flow of participants through each stage of the trial.  
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Table 1. Baseline Demographics and clinical characteristics of patients 
  Mean (SD) 
Age, years 38.7 (12.0) 
Clozapine dose, mg  322.5. (95) 
TNHS score 2.63 (0.79) 
Increase in mass of pillow, grams 0.79 (1.19) 
HADs Anxiety score  4.6 (2.9) 
HADs Depression score  5.8 (2.4) 
EQ-5D Analogue Scale 78.1 (16.5) 
TNHS – Toronto Nocturnal Hypersalivation Scale; HADs – Hospital Anxiety and Depression Scale; EQ-5D - 
EuroQol 5 dimensions.     
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Figure 3. Percentage of TNHS ratings by treatment condition  
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Table 2. Results of all outcome measure in the periods of active treatment and placebo.  
  Treatment 
(n=10/14) 
Placebo 
(n=12/14) 
OR or Adjusted Mean 
Difference (95% CI), p 
value 
Mean TNHS (SD)  1.6 (1.1) 2.3 (1.1)  
TNHS overall responses (%)     0.21 (0.16,  0.28, p<0.001) 
   0  67 (20%) 30 (9%)  
   1  107 (31%) 42 (13%)  
   2  64 (19%) 73 (22%)  
   3  98 (29%) 164 (49%)  
   4  2 (1%) 26 (8%)  
Mean pillow weight, grams (SD) 0.66 (0.82) 0.66 (0.83) 0.00 (-0.120, 0.107), NS 
Mean HADs Anxiety (SD)  5.3 (2.7) 5.9 (4.0) -0.42 (-2.00, 1.17), NS 
Mean HADs Depression (SD) 6.2 (3.7) 6.5 (2.0) 0.18 (-0.92, 1.27), NS 
Mean EQ-5D analogue scale (SD) 71.0 (22.6) 67.8 (16.4) -3.7 (-25.0, 17.7), NS 
EQ-5D Mobility problems   NS 
   None (%) 8 (80%) 7 (58%)  
   Some (%) 2(20%) 5 (42%)  
   A lot (%) 0 (0%) 0 (0%)  
EQ-5D Self-care problems    
   None (%) 9 (90%) 8 (83%)  
   Some (%) 1 (10%) 2 (17%)  
   A lot (%) 0 (0%) 0 (0%)  
EQ-5D Usual activities problems   NS 
   None (%) 5 (50%) 7 (58%)  
   Some (%) 5 (50%) 5 (42%)  
   A lot (%) 0 (0%) 0 (0%)  
EQ-5D Pain/discomfort problems   NS 
   None (%) 6 (60%) 6 (50%)  
   Some (%) 4 (40%) 6 (50%)  
   A lot (%) 0 (0%) 0 (0%)  
EQ-5D Anxiety/depression 
problems 
  NS 
  None (%) 6 (60%) 5 (42%)  
  Some (%) 3 (30%) 7 (58%)  
  A lot (%) 1 (10%) 0 (0%)  
TNHS – Toronto Nocturnal Hypersalivation Scale; HADs – Hospital Anxiety and Depression Scale; EQ-5D - 
EuroQol 5 dimensions. 
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Table 4. Adverse Events recorded during the active and placebo periods.  
  Active 
N 
Placebo 
N 
Washouts  
N 
Total  6 5 10 
   Respiratory  0 0 1 
   Gastro-intestinal  1 2 2 
   Gastro-urinary  0 1 1 
   Musculoskeletal  2 0 0 
   Neurological  2 2 3 
   Psychological  1 0 1 
   Eye, Ear, Nose, Throat  0 0 2 
  
 
